Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug M6229 put to the test in healthy people

NCT ID NCT07285603

Knowledge-focused Sponsor: Matisse Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug, M6229, in 15 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo as a continuous 5-day infusion. The study is complete and focused on safety and drug levels, not on treating any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
M6229

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

15 people

The number who actually took part.

Started

Nov 2024

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of written informed consent * Male or female, aged 18 - 55 years at time of informed consent * BMI between 18.0 - 30.0 kg/m2 * Normal vital signs (resting pulse rate and resting blood pressure) * Normal ECG parameters (PR, QRS, QTc) * Normal coagulation parameters (aPTT, PTT/INR and thrombin time) * Female subjects must have a negative serum pregnancy test * Willing and able to adhere to contraceptive requirements Exclusion Criteria: * History of clinically significant medical illness * Laboratory abnormalities * Major surgery or trauma in previous 6 months * Positive test for HIV, HBsAg, or HCV * History of heart arrhythmias, tachycardia at rest, or history of risk factors for Torsade de Pointes syndrome * Clinically relevant allergy or drug hypersensitivity (incl. heparin) * Smokes daily more than 5 cigarettes or equivalent * History of postural disorders * Lack of adequate venous access * Current or ongoing history of urinary retention * Use of prescription or nonprescription medication within 7 days prior to Day 1 * Received an investigational drug or medical device recently, or \>3 investigational agents in last 12 months, or currently enrolled in an investigational study * Donated blood or substantial blood loss within 60 days prior to Day 1 * Any condition, preplanned surgery or procedure that would interfere with the study conduct and/or with the subject's best interest * Subject is vulnerable * Subject is an employee of the investigator, clinical site, or Sponsor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy subjects are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy subjects

Contacts and locations

Locations

  • Charité Research

    Berlin, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.